2022 World Conference on Lung Cancer (ePosters)-EP08.02-110. Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy

EP08.02-110. Plasma-based Molecular Profiling to Guide Treatment Decisions in Patients with Advanced NSCLC and Limited Tissue Biopsy

Back to course

Pdf Summary

Plasma-based next-generation sequencing (NGS) is becoming a valuable tool for molecular profiling in patients with non-small cell lung cancer (NSCLC) who have limited tissue samples available. This study aimed to determine the frequency of oncogenic drivers detected using plasma NGS and the proportion of patients treated with genotype-directed therapy, as well as survival outcomes.<br /><br />The researchers conducted a retrospective analysis of advanced NSCLC patients who underwent plasma-based NGS testing between August 2017 and March 2019. Plasma circulating tumor DNA (ctDNA) testing was performed using Foundation One Liquid or Guardant 360. Standard tissue genotyping was also conducted when feasible.<br /><br />The study found that plasma-based NGS identified additional driver alterations in 84% of the patients, compared to only 16% in tissue genotyping. The most common driver alterations detected in plasma were MET exon 14 skipping mutation, ALK fusion, RET fusion, BRAF V600, and EGFR exon 20. In terms of treatment decisions, 31% of patients with identified driver alterations in plasma received matched targeted therapy, leading to a median overall survival of 38.7 months. On the other hand, patients without driver alterations identified had a median overall survival of 13.7 months.<br /><br />These findings highlight the importance of plasma-based NGS in identifying actionable driver alterations in NSCLC patients with limited tissue samples. This molecular profiling approach allows for the selection of targeted therapies that can potentially improve patient outcomes. However, further prospective studies are needed to validate these findings and evaluate the long-term benefits of plasma-based molecular profiling in NSCLC treatment decision-making. Overall, plasma-based NGS shows promise as either a complementary or alternative approach to standard tissue genotyping in advanced NSCLC.

Asset Subtitle

Miguel Garcia Pardo

Meta Tag

Speaker Miguel Garcia Pardo

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

plasma-based next-generation sequencing

molecular profiling

non-small cell lung cancer

limited tissue samples

oncogenic drivers

genotype-directed therapy

survival outcomes

circulating tumor DNA

driver alterations

targeted therapy